Oxygenta Pharma

12
Strong Sell
  • Market Cap: Micro Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: INE102E01018
  • NSEID:
  • BSEID: 524636
INR
55.49
0.49 (0.89%)
BSENSE

Dec 17

BSE+NSE Vol: 4.83 k

  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationProfit and Loss Results
Results Snapshot
Figures in Cr
Standalone - Profit And Loss Results
Mar'25
Mar'24
Mar'23
Mar'22
Mar'21
Mar'20
Profit And Loss Analysis Highlights
stock-summary

Net Sales

YoY Growth in year ended Mar 2025 is 175.71% vs 27.93% in Mar 2024

stock-summary

Operating Profit (PBDIT) excl Other Income

YoY Growth in year ended Mar 2025 is -2.56% vs -36.25% in Mar 2024

stock-summary

Interest

YoY Growth in year ended Mar 2025 is 11.78% vs 7.15% in Mar 2024

stock-summary

Profit After Tax

YoY Growth in year ended Mar 2025 is -178.29% vs 69.93% in Mar 2024

Compare Profit and Loss Results of Oxygenta Pharma
Markets Mojo
Figures in Cr
standalone - Profit And Loss Results
Markets Mojo
Markets Mojo
Change(INR)
Change(%)
No of Months
12
12
Operating Income
109.00
386.00
-277.00
-71.76%
Less :Inter divisional transfers
0.00
0.00
0.00
0%
Less: Excise
0.00
0.00
0.00
0%
Net Sales
109.00
386.00
-277.00
-71.76%
Expenditure (Ex Depriciation)
Stock Adjustments
-3.00
-3.00
0.00
0.00%
Raw Materials Consumed
100.00
310.00
-210.00
-67.74%
Power & Fuel Cost
6.00
2.00
4.00
200.00%
Employee Cost
6.00
8.00
-2.00
-25.00%
Operating Expenses
5.00
5.00
0.00
0.00%
General and Administration Expenses
-1.00
-1.00
0.00
0.00%
Selling and Distribution Expenses
0.00
2.00
-2.00
-100.00%
Cost of Software developments
0.00
0.00
0.00
0%
Miscellaneous Expenses
0.00
0.00
0.00
0%
Expenses Capitalised
0.00
0.00
0.00
0%
Total Expenditure
119.00
382.00
-263.00
-68.85%
Operating Profit (PBDIT) excl Other Income
-9.00
3.00
-12.00
-400.00%
Other Income
1.00
0.00
1.00
0%
Operating Profit (PBDIT)
-8.00
4.00
-12.00
-300.00%
Interest
1.00
0.00
1.00
0%
Profit before Depriciation and Tax
-10.00
3.00
-13.00
-433.33%
Depreciation
0.00
2.00
-2.00
-100.00%
Profit Before Taxation & Exceptional Items
-11.00
1.00
-12.00
-1,200.00%
Exceptional Income / Expenses
0.00
0.00
0.00
0%
Profit Before Tax
-11.00
1.00
-12.00
-1,200.00%
Provision for Tax
-1.00
0.00
-1.00
0%
Profit After Tax
-9.00
0.00
-9.00
0%
Extraordinary Items
0.00
0.00
0.00
0%
Adj to Profit After Tax
0.00
0.00
0.00
0%
Profit Balance B/F
-63.00
-11.00
-52.00
-472.73%
Profit Available for appropriations
-73.00
-10.00
-63.00
-630.00%
Appropriations
-73.00
-10.00
-63.00
-630.00%
Equity Dividend (%)
0%
0%
0.00
Earnings Per Share
-2.69
0.115
-2.81
-2,439.13%
Profit And Loss - Net Sales
Net Sales 109.30 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 175.71% vs 27.93% in Mar 2024

Profit And Loss - Operating Profit (PBDIT)
Operating Profit (PBDIT) -9.94 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -2.56% vs -36.25% in Mar 2024

Profit And Loss - Interest
Interest 1.78 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is 11.78% vs 7.15% in Mar 2024

Profit And Loss - Profit After Tax
Profit After Tax -9.68 Cr
in Mar 2025

Figures in Cr
stock-summary

YoY Growth in year ended Mar 2025 is -178.29% vs 69.93% in Mar 2024